Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (121-130 of 252) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study groupDennis A Eichenauer, Henning Bredenfeld, Heinz Haverkamp, et al.
Molecular Cancer Therapeutics|April 29, 2011
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinomaRon D Jachimowicz, Giulio Fracasso, Paul J Yazaki, et al.
European Journal of Haematology|May 7, 2021
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routineNoëlle Sieg, Jan-Hendrik Naendrup, Philipp Gödel, et al.
Frontiers in Oncology|June 11, 2021
Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients - An Analysis of GHSG HD14- and HD17-PatientsJohannes Rosenbrock, Andrés Vásquez-Torres, Horst Mueller, et al.
Blood|October 8, 2005
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivoElke Pogge von Strandmann, Hinrich P Hansen, Katrin S Reiners, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2007
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphomaStephen M Ansell, Steven M Horwitz, Andreas Engert, et al.
Annals of Hematology|November 17, 2022
Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysisJorge Garcia Borrega, Boris Böll, Matthias Kochanek, et al.
Hematological Oncology|March 21, 2022
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study GroupDennis A Eichenauer, Ina Bühnen, Annette Plütschow, et al.
Hemasphere|August 27, 2025
Serum TARC dynamics during anti-PD1-based first-line Hodgkin lymphoma treatment: An analysis from the GHSG NIVAHL trialWouter J Plattel, Sophie Teesink, Lydia Visser, et al.
Frontiers in Oncology|May 22, 2023
Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma- a risk stratified analysis of the GHSG HD17 trialMichael Oertel, Dominik Hering, Christian Baues, et al.
Pageof 26

Showing results (121-130 of 252) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study groupDennis A Eichenauer, Henning Bredenfeld, Heinz Haverkamp, et al.
Molecular Cancer Therapeutics|April 29, 2011
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinomaRon D Jachimowicz, Giulio Fracasso, Paul J Yazaki, et al.
European Journal of Haematology|May 7, 2021
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routineNoëlle Sieg, Jan-Hendrik Naendrup, Philipp Gödel, et al.
Frontiers in Oncology|June 11, 2021
Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients - An Analysis of GHSG HD14- and HD17-PatientsJohannes Rosenbrock, Andrés Vásquez-Torres, Horst Mueller, et al.
Blood|October 8, 2005
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivoElke Pogge von Strandmann, Hinrich P Hansen, Katrin S Reiners, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2007
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphomaStephen M Ansell, Steven M Horwitz, Andreas Engert, et al.
Annals of Hematology|November 17, 2022
Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysisJorge Garcia Borrega, Boris Böll, Matthias Kochanek, et al.
Hematological Oncology|March 21, 2022
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study GroupDennis A Eichenauer, Ina Bühnen, Annette Plütschow, et al.
Hemasphere|August 27, 2025
Serum TARC dynamics during anti-PD1-based first-line Hodgkin lymphoma treatment: An analysis from the GHSG NIVAHL trialWouter J Plattel, Sophie Teesink, Lydia Visser, et al.
Frontiers in Oncology|May 22, 2023
Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma- a risk stratified analysis of the GHSG HD17 trialMichael Oertel, Dominik Hering, Christian Baues, et al.
Pageof 26